Therefore, statins that are substrates of CYP3A are not anticipated to have an effect on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.
Seetõttu statiinid, mis on CYP3A substraatideks, eeldatavasti ei oma toimet prasugreeli farmakokineetikale ega mõjuta tema trombotsüütide agregatsiooni inhibeerivat toimet.